Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929125 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL62505 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL14931005 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL18512921 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL343478 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL18844803 | 0.96 | CYP2C19 (0.62) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL25101160 | 0.95 | CYP2C19 (0.61) | CYP2C19LMNANT5EHIF1AADORA2A | |
| Hydrochloric Acid SCHEMBL5972606 | 0.95 | CYP2C19 (0.61) | CYP2C19LMNANT5EHIF1AADORA2A | |
| SCHEMBL29388779 | 0.95 | CYP2C19 (0.61) | CYP2C19LMNANT5EHIF1AADORA2A | |
| Phosphoric Acid SCHEMBL5747244 | 0.92 | CYP2C19 (0.58) | CYP2C19LMNANT5EHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021748-A1 | Non-Natural Peptides as Models for the Development of Antibiotics | WAYNE STATE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021748-A1 | Non-Natural Peptides as Models for the Development of Antibiotics | MRPL21, SPOUT1, EMG1 | CYP2C19 4861/4885LMNA 2736/4885NT5E 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.